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During preliminary experiments to establish the proportion of virus-coded p24 protein to virus membrane-associated
HLA-DR in gradient-enriched HIV-1 preparations, we became aware of a large variability between experiments. In order to
determine whether HLA-DR-containing cellular material was contaminating the virus preparations, we carried out enrichment
by gradient centrifugation of clarified supernatants from noninfected cells and tested this material for HLA-DR content. We
found that, independently of the cell type used, gradient enrichment resulted in the isolation of large quantities of HLA-DR-
containing material which banded at a density overlapping that of infectious HIV. Electron microscopy of gradient-enriched
preparations from supernatants of virus-infected cells revealed an excess of vesicles with a size range of about 50–500
nm, as opposed to a minor population of virus particles of about 100 nm. Electron micrographs of infected cells showed
polarized vesiculation of the cell membrane, and virus budding was frequently colocalized with nonviral membrane vesicula-
tion. Analysis of the cellular molecules present in the fractions containing virus or exclusively cellular material demonstrated
that virus and cellular vesicles share several cellular antigens, with the exception of CD43 and CD63, found mainly at the
virus surface, and HLA-DQ, which was found only in the cellular vesicles. q 1997 Academic Press
INTRODUCTION brane, whereas others appear to be absent (Hoxie et
al., 1987; Arthur et al., 1992). This phenomenom is not
The human immunodeficiency virus (HIV) infects HIV-specific, since the presence of cellular proteins
predominantly cells of the immune system such as T in the membranes of other retroviruses has been ob-
lymphocytes and macrophages, which carry the CD4 served (Bubbers and Lilly, 1977; Azocar and Essex,
molecule, the principal HIV receptor (reviewed in Sat- 1979; Lee et al., 1982; Lando et al., 1983). HIV-1 and
tentau and Weiss, 1988). The virus life cycle begins simian immunodeficiency virus (SIV) envelopes are
with virus binding and entry into receptor-bearing particularly enriched for HLA class-I and class-II DR
cells, proceeds with replication of the viral genome by molecules (Gelderblom et al., 1987; Henderson et al.,
reverse transcription and proviral integration into the 1987; Schols et al., 1992; Arthur et al., 1992; Cantin et
host cell genome, and ends with the production and al., 1996). However, in none of the studies demonstra-
assembly of new viral proteins and RNA into progeny ting the association of molecules of human origin with
virions (reviewed in Levy, 1994). New particles are HIV or other retroviruses by biochemical or serological
released from the cell by a polarized process of bud- means has the purity of the virus preparation been
ding by which the virus acquires its envelope from the verified. Virus to be used for biochemical and serologi-
plasma membrane (Gelderblom, 1991). cal analyses or as an immunogen is frequently pre-
The viral envelope contains glycoproteins of viral pared by centrifugation through sucrose gradients.
origin, gp120 and gp41, which reach the plasma mem-
The fractions containing viral antigen and/or infectivity
brane through the secretory pathway and which are
are considered to contain a population of relatively
essential for binding and entry of the virions into new
pure virus particles.
target cells (reviewed in Moore et al., 1993). Also pres-
We have analyzed gradient-enriched virus prepara-ent in the HIV envelope are molecules of cellular origin
tions and found that there is contamination with an(Gelderblom et al., 1987; Henderson et al., 1987; Hoxie
excess of nonviral membrane vesicles of cellular ori-et al., 1987; Arthur et al., 1992; Meerloo et al., 1993).
gin. This was the case when the virus was grown inCellular molecules appear to be selectively incorpo-
an immortalized cell line or in activated peripheralrated into virions, since some are overrepresented in
blood mononuclear cells (PBMC). These vesicles,comparison to the relative amount in the cell mem-
which are released from both noninfected and HIV-1-
infected cells, contain a selection of cellular mem-
brane proteins similar to, but not identical to, those in1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (33) 91 26 94 30. E-mail: gluschan@ciml.univ-mrs.fr. the virus particles. Contamination of gradient-en-
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riched virus by vesicles of cellular origin has implica- at 0807 until use. The sucrose concentration of each frac-
tion was determined by refractometry.tions for the preparation and use of vaccine formula-
tions derived from whole-virus preparation.
ELISA assay for HLA-DR
HLA-DR protein in virus and vesicular material wasMATERIALS AND METHODS
quantified by twin-site ELISA. A 96-well ELISA plate
Cell culture and HIV infection (Nunc Life Technologies S.A.R.L., Cergy Pontoise,
France) was coated overnight at 47 with 50 ml/well of 5
The immortalized T (H9) cell line was cultured in RPMI
mg/ml L243 monoclonal antibody (mAb; obtained from the
medium complemented with 10% fetal calf serum, penicil-
American Type Culture Collection) in 0.1 M bicarbonate
lin, and streptomycin (growth medium, GM). PBMC were
buffer, pH 8.6. After washing, nonspecific sites were
from the Marseille Blood Transfusion Center (CTS, Mar-
blocked with PBE (PBS, 5 mM EDTA, 2% BSA, 0.5% NP-
seille, France) and were obtained as a preenriched frac-
40), and 50 ml/well of each of the test samples was incu-
tion from individuals having undergone leukopheresis.
bated overnight at 47. After nine washes with PBS/0.05%
The cells were activated prior to virus infection with 1 mg/
Tween 20, 50 ml of a 1/200 dilution of biotinylated anti-
ml phytohemagglutinin (PHA; Gibco BRL, Cergy Pontoise,
HLA-DR clone B8.12.2 (Immunotech, Marseille, France),
France), then cultured in GM supplemented with 20 IU/
a mAb reactive with an epitope that does not overlap
ml IL-2 (Boehringer Mannheim, France), and infected at
with L243, was added for 1 hr at room temperature (RT).
Day 5 after activation. Virus infection of H9 cells and
After further washing, streptavidin–alkaline phosphatase
activated PBMC was carried out as follows. Fifty million
conjugate (Sigma-Aldrich, St. Quentin Fallavier, France)
cells in 6 ml GM were infected with the HIV-1 molecular
was added at a 1/1000 dilution for 1 hr at RT before
clone Hx10 (Fisher et al., 1988) by agitation of the cells
washing. The rest of the reaction was carried out as
for 2 hr at 377 in the presence of virus at an m.o.i. of
proposed in the instructions for the AMPAK amplification
about 0.1. The cells were then kept at a density of 5 1
kit (DAKO S.A., Trappes, France). The concentration of
105 to 10 1 105/ml, and virus production was followed
HLA-DR present in the sample was quantified by the
by ELISA detection of viral p24 in the culture supernatant
inclusion of a standard curve generated with purified
as previously described (Moore et al., 1990). Culture su-
MHC HLA-DR4. This molecule, derived from insect cells
pernatants from different time points were centrifuged at
coinfected with HLA-DRa and b DAF recombinant bacu-
400 g for 10 min and filtered through 0.45-mm filters to
loviruses (Scheirle et al., 1992) and purified as described
remove gross cell debris, then frozen at 0807. Superna-
elsewhere (Cammarota et al., 1992) was kindly provided
tants subsequently determined as containing the maxi-
by D. Piatier-Tonneau (UPR420 CNRS, Villejuif, France).
mum amount of p24 were used for enrichment of viral
material. Titration of virus infectivity was carried out by Solid-phase antibody capture of virus and cellular
limiting dilution analysis on H9 cells. Briefly, serial five- material and measurement of captured virus
fold dilutions of the virus preparation were incubated infectivity
with 105 H9 cells/well in a U-bottomed 96-well plate. The
tissue culture infectious dose (TCID) was determined as This assay is a modified version of the one described
elsewhere (Abbate et al., 1995). Briefly, 96-well ELISAthe last dilution giving a positive signal for soluble p24
antigen by ELISA on Day 5 after infection. plates were coated with a panel of mAb directed to differ-
ent lymphocyte surface antigens. The mAbs ICO-80,
By88, 10G7, 212.3, and RUU-SP2.28, directed to CD5,Enrichment of HIV and vesicular material
CD30, CD43, CD44, and CD63 were obtained from the
fifth International Leucocyte Typing Workshop antibodyVirus and cellular vesicles were enriched from clarified
cell culture supernatants at the time point giving maximal panel, and mAb SPVL3 directed to HLA-DQ was pur-
chased from Immunotech, France. HLA-DR-positive ma-p24 production in the supernatant of infected cells or the
corresponding time point in uninfected cells, by the follow- terial from infected cell supernatants was captured onto
the solid phase by coating plates with mAb L243 asing procedure. Precleared supernatants were centrifuged
at 70,000 g for 45 min, and the pellet was resuspended in described above. Nonspecific sites were blocked with
PBS/1% FCS (wash buffer, WB) for 1 hr at RT, then 25 ml500 ml of sterile PBS and centrifuged through 1 ml of a
20% sucrose/PBS cushion for 10 min at 70,000 g. The pellet of each fraction from the sucrose gradient was added in
WB to yield a final volume of 100 ml. After 4 hr of incuba-containing virus/cellular material was resuspended in 250
ml of PBS and centrifuged through a discontinuous sucrose tion at RT, the unbound material was removed. To deter-
mine the relative proportion of the different cellular anti-gradient (500 ml of 60% sucrose/PBS / 750 ml of 50%
sucrose/PBS / 750 ml of 40% sucrose/PBS / 750 ml of gens captured onto the solid phase from uninfected cell
supernatants, the bound fractions were analyzed for the30% sucrose/PBS) for 15 min at 100,000 g. Twelve fractions
of 250 ml each were taken from top to bottom, and stored presence of HLA-DR on the surface of cellular vesicles
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FIG. 1. Density gradient purification of HIV-1 and cellular vesicles from supernatants of infected and noninfected cells. Material pelleted at 70,000
g from supernatants of HIV-1-infected H9 cells (a and c) or activated PBMC (b and d) or from supernatants of noninfected H9 cells (e) or activated
PBMC (f) was loaded onto a discontinuous sucrose gradient as described under Materials and Methods. Twelve 250-ml fractions were taken from
top to bottom. The density, amount of p24 capsid (a and b), infectivity (c and d), and HLA-DR antigen (c, d, e and f) were determined for each
fraction.
by ELISA as previously described (in this case, PBE was H9 cells/well in a separate plate, and the TCID was deter-
mined as for the unbound material. All manipulationsreplaced by WB).
The unbound material from infected cell supernatants were carried out under sterile conditions using sterile
buffers and media.was titrated onto 4 1 105 H9 cells/well in a separate
plate, and the TCID was determined by measurement of
Electron microscopic analysis of virus and cellularp24 antigen in the supernatant at Day 7 after infection
vesiclesas previously described. The plate containing the bound
material was washed, and 4 1 105 H9 cells were added. HIV-1 Hx10-infected cells and sucrose-gradient-en-
riched material from infected and noninfected cell cultureAt Day 7, the virus produced was titrated onto 4 1 105
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FIG. 2. Purified HIV-1 preparations are contaminated by cellular vesicles. Purified vesicles from infected H9 cells (a) and activated PBMC (b)
supernatants (fraction 6 from Fig. 1a and fraction 5 from Fig. 1b, respectively) or from noninfected H9 cells (c) (fraction 6 from Fig. 1e) were treated
for electron microscopic analysis as indicated under Materials and Methods. The cellular vesicles appear to be a heterogeneous population of
both electron-lucent and electron-dense membrane delineated vesicles ranging in size from about 50 to 500 nm. (Original magnification 136,000).
Virions are indicated by arrows.
supernatants were fixed in 2.5% glutaraldehyde in PBS cellular origin, might be a contaminant of sucrose gradi-
ent ‘‘purified’’ virus preparations. Indeed, electron micros-at room temperature. The specimens were enclosed into
agarose blocks for ease of handling. After additional copy of the sediments of culture supernatants revealed
treatment with tannic acid and uranyl acetate, the speci- a high proportion of empty, membrane-bound structure
mens were embedded into Epon following routine tech- (data not shown).
niques (Gelderblom et al., 1987). Thin sections were Clarified culture supernatant from noninfected cells
poststained with lead citrate and evaluated using a Zeiss and cells infected with a molecular clone of HIV-1
EM-10 A electron microscope. (Hx10) were fractionated on a discontinuous sucrose
gradient. We quantified the amount of HLA-DR for
each fraction and measured the concentration of p24RESULTS
protein and infectivity for fractions derived from the
infected cellular material. Figure 1 (a to c) shows theIn initial studies in which we attempted to establish
profile of HIV-1-containing fractions obtained fromthe ratio of virion p24 capsid to cellular HLA-DR protein
gradient centrifugation of supernatant from infectedin HIV-1 virion-containing supernatants prepared from a
H9 cells and PHA-activated PBMC. As previously re-variety of different cell lines, we found a very large varia-
ported (Cheng-Mayer et al., 1991), we also observedtion between experiments (data not shown). We therefore
a marked difference in TCID values (about 2 to 3 log)decided to investigate the possibility that cellular mate-
rial containing HLA-DR, and perhaps other molecules of between virus grown in activated PBMC or in a T cell
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FIG. 3. Cellular vesicles and viral particles appear to bud from the same region of the plasma membrane. Infected activated PBMC were treated
for electron microscopy analysis. Polarized HIV budding and cellular vesiculation can be seen at several distinct regions of the cell membrane.
(Original magnification 125,000). Arrows indicate major regions of virus budding and cell membrane vesiculation.
line. Infectious virus particles were found predomi- 50 to 500 nm and either are empty or stain slightly
opaque, are present in the noninfected cellular mate-nantly in fractions 5 and 6, which correspond to a
sucrose density of approximately 1.15. Both p24 and rial. The same vesicles can be seen in the prepara-
tions from the HIV-infected cells along with HIV-1 par-HLA-DR were found in fractions 4 – 7 (sucrose density
1.14 – 1.17), implying that infectivity, p24, and HLA-DR ticles. The majority of the virus particles have the clas-
sical morphology, i.e., they can be identified by theare all associated with material of the same density,
irrespective of the cell type used to grow the virus. relatively homogeneous diameter of about 110 nm, the
dense cone-shaped core, and the ‘‘lateral bodies.’’ InAnalysis of clarified supernatant from uninfected cells,
however, revealed that HLA-DR was also present in addition, a small fraction of immature HIV is also pres-
ent. HIV particles are a minority population, compris-the sucrose gradient (Figs. 1e and 1f). The distribution
through the gradient was similar to the fractionated ing about 25 to 50% of the vesicles in both infected
preparations. We conclude from these results that cel-infected material, in that significant amounts of HLA-
DR were detected between fractions 4 and 7. Thus lular vesicles appear, at least under the culture condi-
tions used here, to be a major contaminant of HIVHLA-DR-containing material present in noninfected
cells has a density overlapping that of HIV-1 particles. preparations enriched by sucrose gradient centrifuga-
tion. In an attempt to define the origin of these vesi-In order to characterize this cellular material, we car-
ried out electron microscopy of sample sediments de- cles, we examined sections of HIV-infected cells for
evidence of vesiculation. As shown in Fig. 3, infectedrived from gradient-prepared supernatants from in-
fected and uninfected cells. Figure 2 shows represen- cells showed polarized vesiculation, yielding mem-
brane vesicles similar to those seen in the gradient-tative sections of the gradient-enriched preparations;
pleomorphic vesicles, which range in size from about enriched material. From the images examined, it ap-
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FIG. 4. Cellular vesicles carry cell membrane-associated antigens at their surface. Vesicles from density-gradient fractionated material obtained
from H9 cells (A) or activated PBMC (B) supernatants were captured onto the solid phase by a panel of mAbs to various cellular antigens. The
capture of bound vesicles was detected by titration of HLA-DR molecules present in the membrane of the vesicle using a twin-site ELISA. mAbs
ICO-80, By88, 10G7, 212.3, RUU-SP2.28, L243, and SPVL3 directed to CD5, CD30, CD43, CD44, CD63, HLA-DR, and HLA-DQ, respectively, were
used for capture, and biotinylated anti-HLA-DR clone B8.12.2 was used for detection.
pears that the cells undergoing vesiculation are shows the presence of the different antigens in the bound
vesicle fractions from noninfected cells. Both H9- andhealthy and not undergoing apoptosis, implying that
such vesiculation may be part of a normal cellular PBMC-derived material contained CD5, HLA-DR, HLA-
DQ, CD30, and CD44, which was broadly distributed be-function.
It has been reported that HIV-1 contains a number of tween fractions 3 and 7, but little or no CD43 and CD63.
The distribution of cellular molecules in the infectious,cellular molecules in addition to HLA-DR. In order to
better define the phenotype of the vesicles released by H9-derived HIV-1-associated fraction was somewhat dif-
ferent from that observed for the cellular vesicles (Fig.noninfected cells, we developed an assay to determine
the presence or absence of different cellular antigens in 5A). Not only were CD5, HLA-DR, and CD44 found to be
associated with infectivity, but also CD43 and CD63,both the virus particle and the cellular vesicle popula-
tions. Gradient-fractionated material was adsorbed to 96- which were not detected in the cellular vesicles. More-
over, HLA-DQ which was associated with the cellularwell plates coated with mAbs specific for seven different
lymphocyte antigens which have previously been deter- vesicles was absent in the infectious fraction. In the in-
fected PBMC-derived material the situation was lessmined to be present on the surface of the cell types used.
Bound and unbound material was separated by washing, clear; although CD63 and HLA-DR were strongly associ-
ated with HIV, CD30, CD44, CD5, and CD43 were lessand the presence of vesicles in the two fractions was
detected by a sandwich ELISA using anti-HLA-DR. The well represented. However, the fact that no CD5-, CD43-,
CD30-, or CD44-positive infectious HIV was recovered inspecificity of the capture system was tested by using
supernatants from infected HLA-DR-negative A3.01 cells. the unbound fraction suggests that the virus population
carrying these antigens may be less infectious than theDespite yielding large amounts of infectious virus, none
of the A3.01-derived material was captured onto HLA- one containing HLA-DR and CD63 in their envelope. The
only antigen which was obviously present in the unboundDR-coated plates, and all was present in the unbound
fraction (data not shown). The presence of cellular anti- fraction was HLA-DQ, confirming that this molecule is ex-
cluded from infectious HIV-1 particles (Fig. 5B). Althoughgens in the virus membrane was determined by measur-
ing the infectivity present in the bound and unbound we were unable to measure the quantity of cellular mole-
cules incorporated into either the cellular vesicles or thefractions derived from PBMC and H9 cells. Figure 4
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FIG. 5. The envelope of infectious viral particles shares some cellular antigens with the membrane of cellular vesicles. Infectious material
present in fractions from density gradient-purified HIV from infected H9 cells (A) or activated PBMC (B) supernatants was captured by a panel
of mAbs to various cellular antigens (as in Fig. 5) in a solid-phase capture system. The amount of infectious viral particles bound or unbound
to the solid support was quantified (TCID/ml) by titration of the virus onto H9 cells and measurement of viral p24 protein in the infected cell
supernatant.
infectious viral fractions, no obvious relationship between of cellular origin are a major contaminant. These vesicles
viral infectivity and the level of expression of these mole- contain a number of molecules of cellular origin, which are
cules at the cell surface (data not shown) could be found. similar to, but not identical to, those found in the virus enve-
lope. At present it is unclear why these cellular vesicles,
many of which appear ‘‘empty’’ by electron microscopy,DISCUSSION
should have the same density as HIV-1 virus particles. One
reason might be that the vesicles contain large amounts ofHere we show that in preparations of the HIV-1 molecular
protein and nucleic acid which are unstructured (Bess et al.,clone Hx10 enriched by sucrose gradient centrifugation from
supernatants obtained from two different cell types, vesicles 1997) and thus are transparent by electron microscopy.
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A large number of studies have used HIV antigen and an equilibrium density of about 1.13 g/ml (Raposo
et al., 1996). At present the role of this vesiculation inwhich has been ‘‘purified’’ by density gradient centrifuga-
tion. Early ELISA tests were based on lysed whole virus normal cell function is undefined, but may involve the
elimination of excess membrane or membrane-associ-obtained from growth in tissue culture; false-positive re-
sults were obtained in a percentage of sera as a result ated proteins or, alternatively, a novel mechanism of anti-
gen presentation (Raposo et al., 1996).of reactivity with HLA-DR antigen present in the viral
lysate (Hunter and Menitove, 1985; Kuhnl et al., 1985). It It is unclear whether the production of cellular vesicles
by the host cell has any significance for virus buddingwas assumed at the time that the contaminating HLA
antigen was contained within the virus membrane (Hen- and release. The finding that many of the cellular mole-
cules found in the virus are also present in the cellularderson et al., 1987), but it now seems likely that much
of the contamination was from cellular vesicles cosedi- vesicles may imply a common pathway. Indeed, the sites
of the budding of virus and the apparent blebbing ofmenting with the virus (this study and (Bess et al., 1997).
Similarly, early vaccine trials were based on the use of nonviral vesicles appear to be colocalized at distinct po-
lar regions of the cell surface (Fig. 3 and results notinactivated material derived from gradient-enriched su-
pernatants from SIV-infected human cells (Desrosiers et shown). Similar colocalization of cellular and viral anti-
gens within regions of intense membrane vesiculational., 1989; Girard et al., 1991; Murphey-Corb et al., 1989).
Other immunogens have taken the form of immunostimu- has been observed in cells infected with Sindbis virus
and undergoing apoptosis (Rosen et al., 1995). It is there-lating complexes (ISCOMS) (Morein et al., 1978, 1984).
When ISCOMS were prepared from material derived from fore interesting to speculate that HIV, and perhaps other
viruses, may benefit from a normal cellular process inHIV-1 grown in human cells, a major contaminant was
found to be human HLA-DR antigen, and sera from ani- order to facilitate exit from the cell. Alternatively, it has
been shown that membrane vesicles accumulate at sitesmals immunized with these ISCOMS had high antibody
titers against human HLA-DR (Henderson et al., 1987). of plasma membrane damage in a process thought to
be involved in membrane repair (Miyake and McNeil,Although some of the antigenic material of cellular origin
present in these vaccine preparations would have been 1995). It may therefore be that HIV budding disrupts
membrane integrity, resulting in the accumulation andcontained within the virus envelope, much would proba-
bly have come from contaminating cellular vesicles. polarized release of such vesicles. Studies concerning
the role of plasma membrane vesiculation in HIV releaseAside from leading to unwanted antigenicity and the
prospect of false-positive results in early ELISA tests, from the cell are currently under way in this laboratory.
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